The estimated Net Worth of Richard Thomas Williams is at least $112 Mille dollars as of 11 March 2022. Dr Williams owns over 40,000 units of Kinnate Biopharma stock worth over $112,182 and over the last 4 years he sold KNTE stock worth over $0.
Dr has made over 1 trades of the Kinnate Biopharma stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 40,000 units of KNTE stock worth $338,800 on 11 March 2022.
The largest trade he's ever made was buying 40,000 units of Kinnate Biopharma stock on 11 March 2022 worth over $338,800. On average, Dr trades about 3,636 units every 0 days since 2021. As of 11 March 2022 he still owns at least 42,333 units of Kinnate Biopharma stock.
You can see the complete history of Dr Williams stock trades at the bottom of the page.
Dr. Richard Thomas Williams MBBS, Ph.D. is the Chief Medical Officer at Kinnate Biopharma.
Dr D is 52, he's been the Chief Medical Officer of Kinnate Biopharma since . There are no older and 5 younger executives at Kinnate Biopharma.
Richard's mailing address filed with the SEC is 800 WEST EL CAMINO REAL, SUITE 180, MOUNTAIN VIEW, CA, 94040.
Over the last 4 years, insiders at Kinnate Biopharma have traded over $0 worth of Kinnate Biopharma stock and bought 12,223,600 units worth $79,803,534 . The most active insiders traders include Carl L Gordon, Advisors Llc Orbi Med Capit... e Helen Sabzevari. On average, Kinnate Biopharma executives and independent directors trade stock every 74 days with the average trade being worth of $2,699,377. The most recent stock trade was executed by James B. Tananbaum on 8 May 2023, trading 1,780,000 units of KNTE stock currently worth $4,984,000.
Kinnate Biopharma Inc., a biopharmaceutical company, focuses on the discovery and development of small molecule kinase inhibitors to treat genomically defined cancers in the United States. The company develops KIN-2787, a rapidly accelerated fibrosarcoma inhibitor for the treatment of patients with lung cancer, melanoma, and other solid tumors; KIN-3248 small-molecule kinase inhibitors that target cancer-associated alterations in fibroblast growth factor receptors FGFR2 and FGFR3 genes; and small molecule research programs, including Cyclin-Dependent Kinase 12(CDK12) inhibitor in its KIN004 program. The company was incorporated in 2018 and is headquartered in San Francisco, California. Kinnate Biopharma Inc. is a former subsidiary of Fount Therapeutics, LLC.
Kinnate Biopharma executives and other stock owners filed with the SEC include: